These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33272623)

  • 1. Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.
    Ishihara O; Klein BM; Arce JC;
    Fertil Steril; 2021 Jun; 115(6):1478-1486. PubMed ID: 33272623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
    Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
    Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
    Arce JC; Andersen AN; Fernández-Sánchez M; Visnova H; Bosch E; García-Velasco JA; Barri P; de Sutter P; Klein BM; Fauser BC
    Fertil Steril; 2014 Dec; 102(6):1633-40.e5. PubMed ID: 25256937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
    Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
    Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial.
    Ishihara O; Arce JC;
    Reprod Biomed Online; 2021 May; 42(5):909-918. PubMed ID: 33722477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
    Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
    Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection.
    Witz CA; Daftary GS; Doody KJ; Park JK; Seifu Y; Yankov VI; Heiser PW;
    Fertil Steril; 2020 Aug; 114(2):321-330. PubMed ID: 32416978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
    Yang R; Zhang Y; Liang X; Song X; Wei Z; Liu J; Yang Y; Tan J; Zhang Q; Sun Y; Wang W; Qian W; Jin L; Wang S; Xu Y; Yang J; Goethberg M; Mannaerts B; Wu W; Zheng Z; Qiao J
    Reprod Biol Endocrinol; 2022 Oct; 20(1):147. PubMed ID: 36195924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa.
    Arce JC; Larsson P; García-Velasco JA
    Reprod Biomed Online; 2020 Oct; 41(4):616-622. PubMed ID: 32819842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin.
    Bissonnette F; Minano Masip J; Kadoch IJ; Librach C; Sampalis J; Yuzpe A
    Fertil Steril; 2021 Apr; 115(4):991-1000. PubMed ID: 33267959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.
    Fernández-Sánchez M; Visnova H; Yuzpe A; Klein BM; Mannaerts B; Arce JC;
    Reprod Biomed Online; 2019 Apr; 38(4):528-537. PubMed ID: 30713022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders.
    Yeung TW; Chai J; Li RH; Lee VC; Ho PC; Ng EH
    Fertil Steril; 2014 Jul; 102(1):108-115.e1. PubMed ID: 24796766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight.
    Višnová H; Papaleo E; Martin FS; Koziol K; Klein BM; Mannaerts B
    Reprod Biomed Online; 2021 Dec; 43(6):1019-1026. PubMed ID: 34756645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ovarian response to follitropin delta in Japanese and White IVF/ICSI patients.
    Ishihara O; Nelson SM; Arce JC
    Reprod Biomed Online; 2022 Jan; 44(1):177-184. PubMed ID: 34799275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Müllerian hormone variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta.
    Nelson SM; Larsson P; Mannaerts BMJL; Nyboe Andersen A; Fauser BCJM
    Clin Endocrinol (Oxf); 2019 May; 90(5):719-726. PubMed ID: 30801744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes.
    Styer AK; Gaskins AJ; Brady PC; Sluss PM; Chavarro JE; Hauser RB; Toth TL
    Fertil Steril; 2015 Nov; 104(5):1153-61.e1-7. PubMed ID: 26315051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.